HC Wainwright Has Bearish Estimate for SXTP FY2025 Earnings

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) – Stock analysts at HC Wainwright dropped their FY2025 earnings estimates for shares of 60 Degrees Pharmaceuticals in a research note issued on Tuesday, January 27th. HC Wainwright analyst M. Keller now expects that the company will post earnings of ($13.63) per share for the year, down from their prior forecast of ($13.56). HC Wainwright has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($5.09) per share.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($2.64) EPS for the quarter, topping analysts’ consensus estimates of ($4.84) by $2.20. The company had revenue of ($0.01) million during the quarter, compared to the consensus estimate of $0.38 million.

A number of other equities research analysts also recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Monday, December 29th. Zacks Research raised shares of 60 Degrees Pharmaceuticals to a “hold” rating in a report on Tuesday, November 18th. Finally, Ascendiant Capital Markets lowered their target price on shares of 60 Degrees Pharmaceuticals from $12.00 to $11.20 and set a “buy” rating on the stock in a research note on Friday, November 28th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, 60 Degrees Pharmaceuticals currently has an average rating of “Hold” and an average target price of $17.60.

60 Degrees Pharmaceuticals Stock Down 6.9%

Shares of NASDAQ SXTP opened at $4.84 on Thursday. 60 Degrees Pharmaceuticals has a 52 week low of $1.36 and a 52 week high of $19.80. The business has a 50-day simple moving average of $3.23 and a two-hundred day simple moving average of $4.74. The company has a market cap of $5.13 million, a P/E ratio of -0.35 and a beta of 2.98.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.